Predicting Pediatric Age-Matched Weight and Body Mass Index

No abstract is available for this paper.

• Publication year

  2014

• Venue

  AAPS Journal

• Publication date

  2014-08-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1208/s12248-014-9657-9PMID 25155824PMCID PMC4389747
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily

  2013cited by this paper
• First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

  2012cited by this paper
• Population Pharmacokinetics of Tenofovir in HIV-1–Infected Pediatric Patients

  2011cited by this paper
• Predicting weight using postmenstrual age – neonates to adults

  2011cited by this paper
• Dosing in Children

  2010cited by this paper
• What is the right dose for children?

  2010cited by this paper
• Pharmacokinetics in special populations

  2009cited by this paper
• Allometric scaling of xenobiotic clearance: Uncertainty versus universality

  2008cited by this paper
• Facilitation of Drug Evaluation in Children by Population Methods and Modelling

  2008cited by this paper
• Population approaches in paediatrics

  2008cited by this paper
• Prediction of Drug Clearance in Children: Impact of Allometric Exponents, Body Weight, and Age

  2007cited by this paper
• Prediction of drug clearance in children from adults: a comparison of several allometric methods.

  2006cited by this paper
• A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans.

  2004cited by this paper
• The predominance of quarter-power scaling in biology

  2004cited by this paper
• 2000 CDC Growth Charts for the United States: methods and development.

  2002cited by this paper
• CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000

  2002cited by this paper
• The NCHS reference and the growth of breast- and bottle-fed infants.

  1998cited by this paper
• A General Model for the Origin of Allometric Scaling Laws in Biology

  1997cited by this paper
• A Size Standard for Pharmacokinetics

  1996cited by this paper
• Development of normalized curves for the international growth reference: historical and technical considerations.

  1987cited by this paper
• Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.

  1984cited by this paper
• Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics

  1982cited by this paper

• Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

  2024cites this paper
• Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling

  2024cites this paper
• Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach

  2024cites this paper
• Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae

  2023cites this paper
• Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

  2022cites this paper
• The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

  2022cites this paper
• Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii

  2022cites this paper
• Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients

  2021cites this paper
• Reduction of quantitative systems pharmacology models using artificial neural networks

  2021cites this paper
• Physiologically based pharmacokinetic‐pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics

  2020cites this paper
• Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase

  2019cites this paper
• Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes

  2019cites this paper
• Relationship between exposure to treosulfan and its monoepoxytransformer – An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation

  2018cites this paper
• Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae

  2016cites this paper
• Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development

  2016cites this paper
• Clinical Pharmacology: Current Topics and Case Studies

  2016cites this paper
• Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents.

  2015cites this paper
• Pharmacokinetic Evaluation of Avicularin Using a Model-Based Development Approach

  2015cites this paper
• Effect of reducing the paediatric stavudine dose by half: a physiologically-based pharmacokinetic model.

  2015cites this paper